As of May 2026, the major-market IL-17 landscape in the reviewed source set is organized around four branded molecules: secukinumab, ixekizumab, bimekizumab, and brodalumab. The class remains strongest in psoriasis and spondyloarthritis, but hidradenitis suppurativa has become a key point of separation for secukinumab and bimekizumab, while sonelokimab is the most visible next-wave entrant approaching a regulatory filing in HS rather than part of a crowded late-stage pack.